1 1

Medical Education Hub

MSKCC State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

MSKCC State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

€40,00 EUR
€40,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.

MSKCC State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

 Include: 11 videos + 12 pdfs, size: 6.4 GB Target Audience: general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers Information:
Date & Location Sunday, October 26, 2025, 9:00 AM – 5:30 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY
Specialties – Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine
Overview
This one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q&A. Now in its 10th year, the 2025 program will focus on:
  • Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)
  • Advances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders
  • Hematologic complications related to cellular therapies and immunotherapies
  • Novel treatment approaches, including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use
The target audience for this symposium includes general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered exclusively in person; a virtual attendance option will not be available. Following the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.
Objectives
At the conclusion of this symposium, attendees will be able to:
  1. Discuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics
  2. Analyze current data and discuss emerging FXI inhibitors
  3. Describe anticomplement therapies
  4. Recognize the challenges in diagnosis and management of hematologic complications of immunotherapy
  Topics:

Sunday, October 26, 2025

Emerging Data on Factor XI Inhibitors 9:00AM – 9:30AM Jeffrey Zwicker, MD
Cryptogenic Stroke and Cancer 9:30AM – 10:00AM Babak Navi, MD
Benefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery 11:00AM – 11:30AM Marc Carrier, MD
Thrombotic Risk in Acute Lymphoblastic Leukemia 11:30AM – 12:00PM Avi Leader, MD
Inherited Hemolytic Anemias: Scientific Advances in Therapeutics 1:30PM – 2:00PM Mohandas Narla, DSc
Anticomplement Therapy for Paroxysmal Nocturnal Hemoglobinuria 2:00PM – 2:30PM david araten, MD
Management of Cold Agglutinin Disease 2:30PM – 3:00PM Rekha Parameswaran, MD
HLH-like Toxicities Secondary to Cancer Immunotherapy 3:30PM – 4:00PM William Johnson, DO
Thrombosis Related to Immune Therapy 4:00PM – 4:30PM Jodi Mones, MD
Updates in Immune Thrombocytopenia 4:30PM – 5:00PM Cy R Wilkins, MD
Transplant-Associated Thrombotic Microangiopathy 5:00PM – 5:30PM Mohammad Alhomoud, MBBS
View full details